September 10, 2025Journal for ImmunoTherapy of CancerOpen Access

Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial

View Full Paper

Ask AI

Bookmark

Overall survival improved to a median of 52.8 months following fecal microbiota transplantation and anti-PD1 therapy.
The objective response rate reached 65% in this trial, indicating effective combination treatment for advanced melanoma.
Combination therapy was noted to be safe, with no patients remaining on anti-PD1 therapy after the trial.
Post hoc analysis revealed specific factors enhanced progression-free survival among responders undergoing fecal microbiota transplantation.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase I trial shows enhanced overall survival and progression-free survival in melanoma patients with anti-PD1 combined with fecal microbiota transplantation, indicating potential for microbiome therapies.

Cite This Study

Hadi et al. (2025) studied this question.

synapsesocial.com/papers/68c240deb210217d6479d302 https://doi.org/10.1136/jitc-2025-012659

View Full Paper

Ask AI

Bookmark

Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial

Key Points

Discussion

Implication

Cite This Study

Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading